Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
News releases from Adaptimmune Therapeutics plc
< Previous
1
2
3
4
5
6
Next >
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
January 13, 2020
Tickers
ADAP
From
GlobeNewswire News Releases
Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma
December 03, 2019
Will enable expedited development and review of ADP-A2M4 with the goal of commercialization in 2022 for patients with few other treatment options
Tickers
ADAP
From
GlobeNewswire News Releases
Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma
November 16, 2019
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update
November 06, 2019
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019
November 01, 2019
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies
October 09, 2019
Key step toward commercial-readiness for ADP-A2M4 therapy with launch planned for 2022
Tickers
ADAP
CYRX
CYRXW
From
GlobeNewswire News Releases
Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer
October 01, 2019
Tickers
ADAP
From
GlobeNewswire News Releases
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO
September 30, 2019
- Clinical responses in 7 out of 12 patients with synovial sarcoma, and clinical benefit in 11 out 12 patients -
Tickers
ADAP
From
GlobeNewswire News Releases
United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4
September 09, 2019
Orphan drug designation is another significant milestone in the ADP-A2M4 program
Tickers
ADAP
From
GlobeNewswire News Releases
New Executive Team Announced at Adaptimmune
August 01, 2019
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update
August 01, 2019
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019
July 29, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Second Quarter 2019 and provide a business update before the U.S. markets...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
July 25, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has started its SPEARHEAD-1 trial with ADP-A2M4 SPEAR T‑cells for patients with synovial sarcoma or myxoid/round...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
July 22, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has initiated a radiation sub-study of its ADP‑A2M4 trial in collaboration with the University of Texas MD...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses
July 18, 2019
These next-generation SPEAR T-cells may improve long term T-cell functions
Tickers
ADAP
From
GlobeNewswire News Releases
Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer
June 27, 2019
James Noble will transition to become a Non-Executive Director
Tickers
ADAP
GWPH
WVE
From
GlobeNewswire News Releases
Adaptimmune Reports First Quarter 2019 Financial Results
May 06, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the first quarter ended March 31, 2019. Adaptimmune shared a clinical update...
Tickers
ADAP
From
GlobeNewswire News Releases
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
May 06, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced significant clinical progress with partial responses in 4 out of 5 synovial sarcoma patients...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting
May 02, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will present new and compelling data during an oral presentation about its off-the-shelf SPEAR T-cell program at...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019
May 01, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will provide a clinical and business update before the U.S. markets open on Monday May 6, 2019. Following the...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting
April 18, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announces an oral presentation by Dr. Jo Brewer, VP of Platform Sciences, summarizing data from Adaptimmune’s...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting
April 02, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial safety data from two patients with advanced hepatocellular carcinoma (HCC), liver cancer, from...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting
April 01, 2019
- Preclinical data show that next generation SPEAR T-cells may improve long term T-cell functions as well as antitumor activity -
Tickers
ADAP
From
GlobeNewswire News Releases
CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
February 27, 2019
In a release issued under the same headline earlier today by Adaptimmune Therapeutics plc (Nasdaq:ADAP), please note that the third subheadline should read, "Treating patients in expansion phases of...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
February 26, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2018 and provided a business...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019
February 07, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Fourth Quarter / Full Year 2018 and provide a general business update...
Tickers
ADAP
From
GlobeNewswire News Releases
Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews
January 06, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the Safety Review Committee (SRC) has endorsed dose escalation in the ongoing ADP-A2AFP...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Announces that Gwen Binder will leave in January 2019
December 12, 2018
Adaptimmune (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that Gwen Binder, PhD, Chief Technology Officer, will be leaving the company at the end of January 2019.
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update
November 05, 2018
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the third quarter ended September 30, 2018, and provided a business update.
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018
October 25, 2018
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Third Quarter 2018 and provide a general business update before the U.S....
Tickers
ADAP
From
GlobeNewswire News Releases
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.